back to cluster viewer
cluster path 111101110110
247 words, 8,505 tokens
freq alpha suffix
Words in frequency order
1 | wk | 3,823
|
2 | mo | 3,102
|
3 | wks | 268
|
4 | a.m. | 246
|
5 | p.m. | 181
|
6 | oz | 97
|
7 | o'clock | 49
|
8 | reps | 46
|
9 | ounces | 33
|
10 | pens/treatment | 32
|
11 | suppl | 23
|
12 | pigs/pen | 21
|
13 | kkw | 20
|
14 | micromol/min | 20
|
15 | polysomy | 16
|
16 | beta-hsd | 14
|
17 | hr/day | 14
|
18 | bcais | 11
|
19 | ects | 11
|
20 | 1/2-year | 10
|
21 | dvu | 10
|
22 | 022 | 9
|
23 | 055 | 9
|
24 | a.m | 9
|
25 | hete | 9
|
26 | replicates/treatment | 9
|
27 | μg/μl | 9
|
28 | nonacupoints | 8
|
29 | 029 | 7
|
30 | episodes/year | 7
|
31 | pigs/treatment | 7
|
32 | 9/l | 6
|
33 | cem43°c | 6
|
34 | dogs/group | 6
|
35 | hooves | 6
|
36 | months- | 6
|
37 | pita | 6
|
38 | t-mr | 6
|
39 | bcai | 5
|
40 | gradia-dp | 5
|
41 | hours/overnight | 5
|
42 | microg/kg/d | 5
|
43 | months.one | 5
|
44 | -week | 4
|
45 | calpas-g | 4
|
46 | repetitions/set | 4
|
47 | weeks.a | 4
|
48 | weeks.one | 4
|
49 | weeks’ | 4
|
50 | -o- | 3
|
51 | 1dpos | 3
|
52 | basc-sr | 3
|
53 | cis-,11 | 3
|
54 | cows/group | 3
|
55 | h-pml | 3
|
56 | lambs/treatment | 3
|
57 | lamellas | 3
|
58 | mg/g/day | 3
|
59 | ml·kg·h | 3
|
60 | mrna/t-bet | 3
|
61 | non-cholestatic | 3
|
62 | participants/study | 3
|
63 | pens/diet | 3
|
64 | placebo→czp | 3
|
65 | post-gnrh | 3
|
66 | segments/patient | 3
|
67 | tpes | 3
|
68 | ucots | 3
|
69 | weeks- | 3
|
70 | weeks.we | 3
|
71 | 113tyr-139arg | 2
|
72 | alpha-hydroxylation | 2
|
73 | b150 | 2
|
74 | basal/6 | 2
|
75 | cages/treatment | 2
|
76 | cellobiohydrolases | 2
|
77 | children/adolescent | 2
|
78 | ci/μmol | 2
|
79 | cigarette/day | 2
|
80 | copd-ex-smokers | 2
|
81 | h-light | 2
|
82 | heifers/treatment | 2
|
83 | lbds | 2
|
84 | lead-qrs | 2
|
85 | linomide | 2
|
86 | m-11 | 2
|
87 | mg/kg/b.wt. | 2
|
88 | microsv | 2
|
89 | min/bed | 2
|
90 | ml.kg.km | 2
|
91 | mo-17 | 2
|
92 | mo-4 | 2
|
93 | mo-6 | 2
|
94 | mo-7 | 2
|
95 | months-baseline | 2
|
96 | months-were | 2
|
97 | months.in | 2
|
98 | months/year | 2
|
99 | months’ | 2
|
100 | morphparents | 2
|
101 | m€ | 2
|
102 | o'clock-hour | 2
|
103 | post-estrus | 2
|
104 | rjs | 2
|
105 | rqolq-eec | 2
|
106 | sca31 | 2
|
107 | stain-positive | 2
|
108 | thickenning | 2
|
109 | times/m | 2
|
110 | weeks.following | 2
|
111 | weeks׳ | 2
|
112 | wk-old | 2
|
113 | year-follow-up | 2
|
114 | β-agarase | 2
|
115 | 'turbp | 1
|
116 | -octadecanoate | 1
|
117 | 053.0 | 1
|
118 | 1/3-7 | 1
|
119 | 365/2 | 1
|
120 | 383.3 | 1
|
121 | 51-77years | 1
|
122 | 656.80 | 1
|
123 | 65±7 | 1
|
124 | 716.1±2 | 1
|
125 | a.m.-midnight | 1
|
126 | alloherpeviruses | 1
|
127 | am-10 | 1
|
128 | am-2 | 1
|
129 | am-4:00 | 1
|
130 | am-5 | 1
|
131 | am-6 | 1
|
132 | am/8 | 1
|
133 | animals/groups | 1
|
134 | assessments/day | 1
|
135 | base-out/3 | 1
|
136 | bears/group | 1
|
137 | bilateral-bifrontal | 1
|
138 | birds/replication | 1
|
139 | bulls/herd | 1
|
140 | bw/session | 1
|
141 | cats/diet | 1
|
142 | cats/group | 1
|
143 | cattle/treatment | 1
|
144 | cells/visual | 1
|
145 | chicks/pen | 1
|
146 | chronically-medicated | 1
|
147 | co-educational | 1
|
148 | confinements | 1
|
149 | cytokines/ | 1
|
150 | d/60 | 1
|
151 | days+therapeutically | 1
|
152 | days/phase | 1
|
153 | dipteryxalata | 1
|
154 | dm-spect | 1
|
155 | dogs/treatment | 1
|
156 | doses/hour | 1
|
157 | dp-system | 1
|
158 | eggs/test | 1
|
159 | f/3d | 1
|
160 | females,65 | 1
|
161 | females/cage | 1
|
162 | females/treatment | 1
|
163 | fog-r | 1
|
164 | fractions/wk | 1
|
165 | g/package | 1
|
166 | gafter | 1
|
167 | geese/replicate | 1
|
168 | gpa/900 | 1
|
169 | gy/6 | 1
|
170 | h.the | 1
|
171 | h/74 | 1
|
172 | h/d,3 | 1
|
173 | heifers/pasture | 1
|
174 | hours-40 | 1
|
175 | hr/x3/week | 1
|
176 | hydroxyatx | 1
|
177 | images/cycles | 1
|
178 | information-type | 1
|
179 | intestinal-content | 1
|
180 | k/ul | 1
|
181 | kcal/kg/wk | 1
|
182 | l6-13 | 1
|
183 | lambs/pen | 1
|
184 | mabp-21.52 | 1
|
185 | mares/group/mo | 1
|
186 | mcg/kg/l | 1
|
187 | mg/head/day | 1
|
188 | mg/heifer/d | 1
|
189 | mg/kg-lycopene | 1
|
190 | mg/kg/hours | 1
|
191 | mg/min/ml | 1
|
192 | mg/ml.min | 1
|
193 | mice/ | 1
|
194 | mice/dose/sex | 1
|
195 | microliter/ml | 1
|
196 | miles/h | 1
|
197 | minutes/nostril | 1
|
198 | ml.kg-1.hr-1 | 1
|
199 | ml.m-2 | 1
|
200 | ml/ample | 1
|
201 | ml/kgbw/min | 1
|
202 | ml/nerve | 1
|
203 | ml/site | 1
|
204 | ml·kg-1·d-1 | 1
|
205 | ml·kg−¹·min−¹ | 1
|
206 | mo-16 | 1
|
207 | mo-20 | 1
|
208 | mo-5 | 1
|
209 | mo-9 | 1
|
210 | month-term | 1
|
211 | months-post | 1
|
212 | months-suggests | 1
|
213 | months.eight | 1
|
214 | months/initiation | 1
|
215 | mos-1 | 1
|
216 | mujin-related | 1
|
217 | nmol/cm2/min | 1
|
218 | non-disorders | 1
|
219 | non-ehr-using | 1
|
220 | normocalcemics | 1
|
221 | packets/day | 1
|
222 | patients/17 | 1
|
223 | pesso | 1
|
224 | phase-2/3 | 1
|
225 | posterior/posterolateral | 1
|
226 | purchases/y | 1
|
227 | pwt/lvidd | 1
|
228 | regions-medial | 1
|
229 | replacements/removals | 1
|
230 | sheep/group | 1
|
231 | spots/session | 1
|
232 | s±12.3 | 1
|
233 | tp53del/wt | 1
|
234 | uplandicum | 1
|
235 | vital/ | 1
|
236 | w/17m | 1
|
237 | wbc/high-power | 1
|
238 | weeks-delivery | 1
|
239 | weeks. | 1
|
240 | weeks/device | 1
|
241 | weeks/period | 1
|
242 | wks-14 | 1
|
243 | women/day | 1
|
244 | µa | 1
|
245 | ǻ | 1
|
246 | μg/breath | 1
|
247 | ⩾34weeks | 1
|
Words in alphabetical order
1 | 'turbp | 1
|
2 | -o- | 3
|
3 | -octadecanoate | 1
|
4 | -week | 4
|
5 | 022 | 9
|
6 | 029 | 7
|
7 | 053.0 | 1
|
8 | 055 | 9
|
9 | 1/2-year | 10
|
10 | 1/3-7 | 1
|
11 | 113tyr-139arg | 2
|
12 | 1dpos | 3
|
13 | 365/2 | 1
|
14 | 383.3 | 1
|
15 | 51-77years | 1
|
16 | 656.80 | 1
|
17 | 65±7 | 1
|
18 | 716.1±2 | 1
|
19 | 9/l | 6
|
20 | a.m | 9
|
21 | a.m. | 246
|
22 | a.m.-midnight | 1
|
23 | alloherpeviruses | 1
|
24 | alpha-hydroxylation | 2
|
25 | am-10 | 1
|
26 | am-2 | 1
|
27 | am-4:00 | 1
|
28 | am-5 | 1
|
29 | am-6 | 1
|
30 | am/8 | 1
|
31 | animals/groups | 1
|
32 | assessments/day | 1
|
33 | b150 | 2
|
34 | basal/6 | 2
|
35 | basc-sr | 3
|
36 | base-out/3 | 1
|
37 | bcai | 5
|
38 | bcais | 11
|
39 | bears/group | 1
|
40 | beta-hsd | 14
|
41 | bilateral-bifrontal | 1
|
42 | birds/replication | 1
|
43 | bulls/herd | 1
|
44 | bw/session | 1
|
45 | cages/treatment | 2
|
46 | calpas-g | 4
|
47 | cats/diet | 1
|
48 | cats/group | 1
|
49 | cattle/treatment | 1
|
50 | cellobiohydrolases | 2
|
51 | cells/visual | 1
|
52 | cem43°c | 6
|
53 | chicks/pen | 1
|
54 | children/adolescent | 2
|
55 | chronically-medicated | 1
|
56 | ci/μmol | 2
|
57 | cigarette/day | 2
|
58 | cis-,11 | 3
|
59 | co-educational | 1
|
60 | confinements | 1
|
61 | copd-ex-smokers | 2
|
62 | cows/group | 3
|
63 | cytokines/ | 1
|
64 | d/60 | 1
|
65 | days+therapeutically | 1
|
66 | days/phase | 1
|
67 | dipteryxalata | 1
|
68 | dm-spect | 1
|
69 | dogs/group | 6
|
70 | dogs/treatment | 1
|
71 | doses/hour | 1
|
72 | dp-system | 1
|
73 | dvu | 10
|
74 | ects | 11
|
75 | eggs/test | 1
|
76 | episodes/year | 7
|
77 | f/3d | 1
|
78 | females,65 | 1
|
79 | females/cage | 1
|
80 | females/treatment | 1
|
81 | fog-r | 1
|
82 | fractions/wk | 1
|
83 | g/package | 1
|
84 | gafter | 1
|
85 | geese/replicate | 1
|
86 | gpa/900 | 1
|
87 | gradia-dp | 5
|
88 | gy/6 | 1
|
89 | h-light | 2
|
90 | h-pml | 3
|
91 | h.the | 1
|
92 | h/74 | 1
|
93 | h/d,3 | 1
|
94 | heifers/pasture | 1
|
95 | heifers/treatment | 2
|
96 | hete | 9
|
97 | hooves | 6
|
98 | hours-40 | 1
|
99 | hours/overnight | 5
|
100 | hr/day | 14
|
101 | hr/x3/week | 1
|
102 | hydroxyatx | 1
|
103 | images/cycles | 1
|
104 | information-type | 1
|
105 | intestinal-content | 1
|
106 | k/ul | 1
|
107 | kcal/kg/wk | 1
|
108 | kkw | 20
|
109 | l6-13 | 1
|
110 | lambs/pen | 1
|
111 | lambs/treatment | 3
|
112 | lamellas | 3
|
113 | lbds | 2
|
114 | lead-qrs | 2
|
115 | linomide | 2
|
116 | m-11 | 2
|
117 | mabp-21.52 | 1
|
118 | mares/group/mo | 1
|
119 | mcg/kg/l | 1
|
120 | mg/g/day | 3
|
121 | mg/head/day | 1
|
122 | mg/heifer/d | 1
|
123 | mg/kg-lycopene | 1
|
124 | mg/kg/b.wt. | 2
|
125 | mg/kg/hours | 1
|
126 | mg/min/ml | 1
|
127 | mg/ml.min | 1
|
128 | mice/ | 1
|
129 | mice/dose/sex | 1
|
130 | microg/kg/d | 5
|
131 | microliter/ml | 1
|
132 | micromol/min | 20
|
133 | microsv | 2
|
134 | miles/h | 1
|
135 | min/bed | 2
|
136 | minutes/nostril | 1
|
137 | ml.kg-1.hr-1 | 1
|
138 | ml.kg.km | 2
|
139 | ml.m-2 | 1
|
140 | ml/ample | 1
|
141 | ml/kgbw/min | 1
|
142 | ml/nerve | 1
|
143 | ml/site | 1
|
144 | ml·kg-1·d-1 | 1
|
145 | ml·kg·h | 3
|
146 | ml·kg−¹·min−¹ | 1
|
147 | mo | 3,102
|
148 | mo-16 | 1
|
149 | mo-17 | 2
|
150 | mo-20 | 1
|
151 | mo-4 | 2
|
152 | mo-5 | 1
|
153 | mo-6 | 2
|
154 | mo-7 | 2
|
155 | mo-9 | 1
|
156 | month-term | 1
|
157 | months- | 6
|
158 | months-baseline | 2
|
159 | months-post | 1
|
160 | months-suggests | 1
|
161 | months-were | 2
|
162 | months.eight | 1
|
163 | months.in | 2
|
164 | months.one | 5
|
165 | months/initiation | 1
|
166 | months/year | 2
|
167 | months’ | 2
|
168 | morphparents | 2
|
169 | mos-1 | 1
|
170 | mrna/t-bet | 3
|
171 | mujin-related | 1
|
172 | m€ | 2
|
173 | nmol/cm2/min | 1
|
174 | non-cholestatic | 3
|
175 | non-disorders | 1
|
176 | non-ehr-using | 1
|
177 | nonacupoints | 8
|
178 | normocalcemics | 1
|
179 | o'clock | 49
|
180 | o'clock-hour | 2
|
181 | ounces | 33
|
182 | oz | 97
|
183 | p.m. | 181
|
184 | packets/day | 1
|
185 | participants/study | 3
|
186 | patients/17 | 1
|
187 | pens/diet | 3
|
188 | pens/treatment | 32
|
189 | pesso | 1
|
190 | phase-2/3 | 1
|
191 | pigs/pen | 21
|
192 | pigs/treatment | 7
|
193 | pita | 6
|
194 | placebo→czp | 3
|
195 | polysomy | 16
|
196 | post-estrus | 2
|
197 | post-gnrh | 3
|
198 | posterior/posterolateral | 1
|
199 | purchases/y | 1
|
200 | pwt/lvidd | 1
|
201 | regions-medial | 1
|
202 | repetitions/set | 4
|
203 | replacements/removals | 1
|
204 | replicates/treatment | 9
|
205 | reps | 46
|
206 | rjs | 2
|
207 | rqolq-eec | 2
|
208 | sca31 | 2
|
209 | segments/patient | 3
|
210 | sheep/group | 1
|
211 | spots/session | 1
|
212 | stain-positive | 2
|
213 | suppl | 23
|
214 | s±12.3 | 1
|
215 | t-mr | 6
|
216 | thickenning | 2
|
217 | times/m | 2
|
218 | tp53del/wt | 1
|
219 | tpes | 3
|
220 | ucots | 3
|
221 | uplandicum | 1
|
222 | vital/ | 1
|
223 | w/17m | 1
|
224 | wbc/high-power | 1
|
225 | weeks- | 3
|
226 | weeks-delivery | 1
|
227 | weeks. | 1
|
228 | weeks.a | 4
|
229 | weeks.following | 2
|
230 | weeks.one | 4
|
231 | weeks.we | 3
|
232 | weeks/device | 1
|
233 | weeks/period | 1
|
234 | weeks׳ | 2
|
235 | weeks’ | 4
|
236 | wk | 3,823
|
237 | wk-old | 2
|
238 | wks | 268
|
239 | wks-14 | 1
|
240 | women/day | 1
|
241 | year-follow-up | 2
|
242 | µa | 1
|
243 | ǻ | 1
|
244 | β-agarase | 2
|
245 | μg/breath | 1
|
246 | μg/μl | 9
|
247 | ⩾34weeks | 1
|
Words in suffix order
1 | -o- | 3
|
2 | months- | 6
|
3 | weeks- | 3
|
4 | a.m. | 246
|
5 | p.m. | 181
|
6 | weeks. | 1
|
7 | mg/kg/b.wt. | 2
|
8 | mice/ | 1
|
9 | vital/ | 1
|
10 | cytokines/ | 1
|
11 | 053.0 | 1
|
12 | gpa/900 | 1
|
13 | am-4:00 | 1
|
14 | am-10 | 1
|
15 | mo-20 | 1
|
16 | hours-40 | 1
|
17 | b150 | 2
|
18 | d/60 | 1
|
19 | 656.80 | 1
|
20 | ml·kg-1·d-1 | 1
|
21 | ml.kg-1.hr-1 | 1
|
22 | mos-1 | 1
|
23 | cis-,11 | 3
|
24 | m-11 | 2
|
25 | sca31 | 2
|
26 | ml.m-2 | 1
|
27 | am-2 | 1
|
28 | 365/2 | 1
|
29 | 022 | 9
|
30 | mabp-21.52 | 1
|
31 | 716.1±2 | 1
|
32 | h/d,3 | 1
|
33 | s±12.3 | 1
|
34 | 383.3 | 1
|
35 | phase-2/3 | 1
|
36 | base-out/3 | 1
|
37 | l6-13 | 1
|
38 | mo-4 | 2
|
39 | wks-14 | 1
|
40 | h/74 | 1
|
41 | am-5 | 1
|
42 | mo-5 | 1
|
43 | 055 | 9
|
44 | females,65 | 1
|
45 | am-6 | 1
|
46 | mo-6 | 2
|
47 | basal/6 | 2
|
48 | gy/6 | 1
|
49 | mo-16 | 1
|
50 | 1/3-7 | 1
|
51 | mo-7 | 2
|
52 | mo-17 | 2
|
53 | patients/17 | 1
|
54 | 65±7 | 1
|
55 | am/8 | 1
|
56 | mo-9 | 1
|
57 | 029 | 7
|
58 | weeks.a | 4
|
59 | dipteryxalata | 1
|
60 | pita | 6
|
61 | µa | 1
|
62 | rqolq-eec | 2
|
63 | non-cholestatic | 3
|
64 | cem43°c | 6
|
65 | microg/kg/d | 5
|
66 | mg/heifer/d | 1
|
67 | f/3d | 1
|
68 | pwt/lvidd | 1
|
69 | min/bed | 2
|
70 | chronically-medicated | 1
|
71 | mujin-related | 1
|
72 | wk-old | 2
|
73 | weeks/period | 1
|
74 | bulls/herd | 1
|
75 | beta-hsd | 14
|
76 | weeks/device | 1
|
77 | linomide | 2
|
78 | females/cage | 1
|
79 | g/package | 1
|
80 | h.the | 1
|
81 | ml/ample | 1
|
82 | mg/kg-lycopene | 1
|
83 | months-baseline | 2
|
84 | months.one | 5
|
85 | weeks.one | 4
|
86 | information-type | 1
|
87 | months-were | 2
|
88 | heifers/pasture | 1
|
89 | days/phase | 1
|
90 | β-agarase | 2
|
91 | geese/replicate | 1
|
92 | -octadecanoate | 1
|
93 | hete | 9
|
94 | ml/site | 1
|
95 | stain-positive | 2
|
96 | ml/nerve | 1
|
97 | weeks.we | 3
|
98 | calpas-g | 4
|
99 | thickenning | 2
|
100 | non-ehr-using | 1
|
101 | weeks.following | 2
|
102 | 113tyr-139arg | 2
|
103 | miles/h | 1
|
104 | post-gnrh | 3
|
105 | μg/breath | 1
|
106 | ml·kg·h | 3
|
107 | bcai | 5
|
108 | o'clock | 49
|
109 | -week | 4
|
110 | hr/x3/week | 1
|
111 | wk | 3,823
|
112 | kcal/kg/wk | 1
|
113 | fractions/wk | 1
|
114 | 9/l | 6
|
115 | mcg/kg/l | 1
|
116 | regions-medial | 1
|
117 | co-educational | 1
|
118 | posterior/posterolateral | 1
|
119 | bilateral-bifrontal | 1
|
120 | cells/visual | 1
|
121 | minutes/nostril | 1
|
122 | mg/min/ml | 1
|
123 | microliter/ml | 1
|
124 | h-pml | 3
|
125 | ci/μmol | 2
|
126 | suppl | 23
|
127 | k/ul | 1
|
128 | μg/μl | 9
|
129 | a.m | 9
|
130 | times/m | 2
|
131 | w/17m | 1
|
132 | dp-system | 1
|
133 | ml.kg.km | 2
|
134 | month-term | 1
|
135 | uplandicum | 1
|
136 | lambs/pen | 1
|
137 | pigs/pen | 21
|
138 | chicks/pen | 1
|
139 | months.in | 2
|
140 | mg/ml.min | 1
|
141 | nmol/cm2/min | 1
|
142 | micromol/min | 20
|
143 | ml/kgbw/min | 1
|
144 | spots/session | 1
|
145 | bw/session | 1
|
146 | birds/replication | 1
|
147 | months/initiation | 1
|
148 | alpha-hydroxylation | 2
|
149 | mo | 3,102
|
150 | mares/group/mo | 1
|
151 | pesso | 1
|
152 | 'turbp | 1
|
153 | gradia-dp | 5
|
154 | year-follow-up | 2
|
155 | sheep/group | 1
|
156 | dogs/group | 6
|
157 | bears/group | 1
|
158 | cats/group | 1
|
159 | cows/group | 3
|
160 | placebo→czp | 3
|
161 | fog-r | 1
|
162 | 1/2-year | 10
|
163 | episodes/year | 7
|
164 | months/year | 2
|
165 | gafter | 1
|
166 | wbc/high-power | 1
|
167 | t-mr | 6
|
168 | basc-sr | 3
|
169 | o'clock-hour | 2
|
170 | doses/hour | 1
|
171 | lamellas | 3
|
172 | normocalcemics | 1
|
173 | lbds | 2
|
174 | ounces | 33
|
175 | images/cycles | 1
|
176 | tpes | 3
|
177 | cellobiohydrolases | 2
|
178 | alloherpeviruses | 1
|
179 | hooves | 6
|
180 | bcais | 11
|
181 | rjs | 2
|
182 | ⩾34weeks | 1
|
183 | wks | 268
|
184 | replacements/removals | 1
|
185 | 1dpos | 3
|
186 | reps | 46
|
187 | animals/groups | 1
|
188 | 51-77years | 1
|
189 | non-disorders | 1
|
190 | copd-ex-smokers | 2
|
191 | lead-qrs | 2
|
192 | mg/kg/hours | 1
|
193 | ects | 11
|
194 | confinements | 1
|
195 | morphparents | 2
|
196 | nonacupoints | 8
|
197 | ucots | 3
|
198 | months-suggests | 1
|
199 | post-estrus | 2
|
200 | dm-spect | 1
|
201 | mrna/t-bet | 3
|
202 | pens/diet | 3
|
203 | cats/diet | 1
|
204 | repetitions/set | 4
|
205 | months.eight | 1
|
206 | h-light | 2
|
207 | a.m.-midnight | 1
|
208 | hours/overnight | 5
|
209 | children/adolescent | 2
|
210 | segments/patient | 3
|
211 | cattle/treatment | 1
|
212 | lambs/treatment | 3
|
213 | cages/treatment | 2
|
214 | females/treatment | 1
|
215 | replicates/treatment | 9
|
216 | pigs/treatment | 7
|
217 | dogs/treatment | 1
|
218 | pens/treatment | 32
|
219 | heifers/treatment | 2
|
220 | intestinal-content | 1
|
221 | eggs/test | 1
|
222 | months-post | 1
|
223 | tp53del/wt | 1
|
224 | dvu | 10
|
225 | microsv | 2
|
226 | kkw | 20
|
227 | mice/dose/sex | 1
|
228 | hydroxyatx | 1
|
229 | purchases/y | 1
|
230 | mg/head/day | 1
|
231 | cigarette/day | 2
|
232 | mg/g/day | 3
|
233 | women/day | 1
|
234 | hr/day | 14
|
235 | packets/day | 1
|
236 | assessments/day | 1
|
237 | participants/study | 3
|
238 | days+therapeutically | 1
|
239 | polysomy | 16
|
240 | weeks-delivery | 1
|
241 | oz | 97
|
242 | months’ | 2
|
243 | weeks’ | 4
|
244 | m€ | 2
|
245 | weeks׳ | 2
|
246 | ml·kg−¹·min−¹ | 1
|
247 | ǻ | 1
|